ALC vs IDXX

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus 4. 9% for Alcon Inc. (ALC). Alcon Inc. (ALC) offers the better valuation at 32. 3x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate Alcon Inc. (ALC) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alcon Inc.

(ALC) is the cheapest at 32. 3x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, Alcon Inc. is actually cheaper at 18. 8x.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -6. 7% for Alcon Inc. (ALC). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus ALC's +13. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alcon Inc.

(ALC) is the lower-risk stock at 0. 80β versus IDEXX Laboratories, Inc. 's 1. 35β — meaning IDXX is approximately 68% more volatile than ALC relative to the S&P 500. On balance sheet safety, Alcon Inc. (ALC) carries a lower debt/equity ratio of 24% versus 67% for IDEXX Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus 4. 9% for Alcon Inc. (ALC). On earnings-per-share growth, the picture is similar: IDEXX Laboratories, Inc. grew EPS 22. 6% year-over-year, compared to -3. 4% for Alcon Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IDEXX Laboratories, Inc.

(IDXX) is the more profitable company, earning 24. 6% net margin versus 9. 4% for Alcon Inc. — meaning it keeps 24. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus 13. 1% for ALC. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Alcon Inc.

(ALC) trades at 18. 8x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 20. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALC: 46. 2% to $93. 36.

In this comparison, ALC (0.

5% yield) pays a dividend. IDXX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alcon Inc.

(ALC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 80), 0. 5% yield). Both have compounded well over 10 years (ALC: +13. 0%, IDXX: +556. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ALC pays a dividend while IDXX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.